BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29931180)

  • 1. Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
    Gill RR; Yeap BY; Bueno R; Richards WG
    J Natl Cancer Inst; 2018 Mar; 110(3):258-264. PubMed ID: 29931180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.
    Gill RR; Naidich DP; Mitchell A; Ginsberg M; Erasmus J; Armato SG; Straus C; Katz S; Patios D; Richards WG; Rusch VW;
    J Thorac Oncol; 2016 Aug; 11(8):1335-1344. PubMed ID: 27180318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
    Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
    J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
    Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
    Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial analysis of the international association for the study of lung cancer mesothelioma database.
    Rusch VW; Giroux D; Kennedy C; Ruffini E; Cangir AK; Rice D; Pass H; Asamura H; Waller D; Edwards J; Weder W; Hoffmann H; van Meerbeeck JP;
    J Thorac Oncol; 2012 Nov; 7(11):1631-9. PubMed ID: 23070243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
    de Perrot M; Dong Z; Bradbury P; Patsios D; Keshavjee S; Leighl NB; Hope A; Feld R; Cho J
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28298401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
    Domen A; De Laet C; Vanderbruggen W; Gielis J; Hendriks JM; Lauwers P; Janssens A; Hiddinga B; Van Meerbeeck JP; Van Schil PE
    Acta Chir Belg; 2017 Jun; 117(3):157-163. PubMed ID: 28399779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
    Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
    PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
    Friedberg JS; Simone CB; Culligan MJ; Barsky AR; Doucette A; McNulty S; Hahn SM; Alley E; Sterman DH; Glatstein E; Cengel KA
    Ann Thorac Surg; 2017 Mar; 103(3):912-919. PubMed ID: 27825687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
    Rusch VW; Gill R; Mitchell A; Naidich D; Rice DC; Pass HI; Kindler HL; De Perrot M; Friedberg J;
    Ann Thorac Surg; 2016 Oct; 102(4):1059-66. PubMed ID: 27596916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
    Abdel-Rahman O
    Lung Cancer; 2017 Nov; 113():128-133. PubMed ID: 29110839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
    Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
    J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
    Komurcuoglu B; Cirak AK; Kirakli SC; Polat G; Yucel N; Usluer O; Erer O; Balci G; Gayaf M; Guldaval F; Aktogu S; Guclu S; Ozsoz A; Halilcolar H
    Tumori; 2014; 100(1):55-9. PubMed ID: 24675492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.